Hepatitis B News and Research

Latest Hepatitis B News and Research

Soligenix announces personalized medicine collaboration with SciClone

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942.

8 Jul 2013

State highlights: Docs prescribe narcotics too often, CDC chief says; Fla. hospices get close scrutiny; Calif. Medi-Cal provider rate bump delayed

The nation's top public health official on Tuesday sharply criticized the widespread treatment of aches and pains with narcotics, saying that doctors are prescribing such drugs too soon, too often and for too long -- putting patients at risk of addiction and overdose. Dr. Tom Frieden, director of the U.S. Centers for Disease Control and Prevention, said that doctors are relying on these powerful drugs to treat chronic pain when physical therapy, exercise and other remedies would be safer and in many cases more effective (Girion and Glover, 7/2).

4 Jul 2013

First Edition: July 3, 2013

Today's headlines detail the Obama administration announcement that it would delay the health law rule requiring businesses provide insurance to workers.

3 Jul 2013

UH and Case Western Reserve University to develop diagnostic tests to determine HIV drug resistance

Case Western Reserve University has signed an exclusive worldwide licensing agreement granting University Hospitals Case Medical Center rights to a series of diagnostic tests to determine drug resistance and co-receptor tropism in human immunodeficiency virus.

2 Jul 2013

New WHO guidelines recommend earlier treatment for people living with HIV

New HIV treatment guidelines by WHO recommend offering antiretroviral therapy earlier. Recent evidence indicates that earlier ART will help people with HIV to live longer, healthier lives, and substantially reduce the risk of transmitting HIV to others.

1 Jul 2013

FDA to restrain shipments of pomegranate seeds from Turkey after hepatitis A outbreak

The U.S. Food and Drug Administration will detain shipments of pomegranate seeds from Goknur Gida Maddeleri Ithalat Ihracat Tic [Goknur Foodstuffs Import Export Trading] of Turkey when they are offered for import into the United States.

1 Jul 2013

Health panel urges baby boomers be tested for hepatitis C

An influential health advisory group has reversed itself and concluded that all baby boomers should be tested for hepatitis C, meaning that under the new health law many insurance plans will have to provide screening without charge to patients.

26 Jun 2013

First Edition: June 25, 2013

Today's headlines include reports about the Obama administraiton's plans for getting the word about the health law's online marketplaces.

25 Jun 2013

Abbott RealTime HCV Genotype II assay receives FDA approval

The U.S. Food and Drug Administration today approved a test that identifies the genotype of hepatitis C virus that a patient is carrying. The Abbott RealTime HCV Genotype II, which can differentiate genotypes 1, 1a, 1b, 2, 3, 4, and 5,using a sample of an infected patient's blood plasma or serum, will aid health care professionals in determining the appropriate approach to treatment.

21 Jun 2013

Accenture: Boom ahead for retail health clinics

According to the consulting firm Accenture, the number of retail clinics will likely double by the end of 2015 -- a trend fueled by the demand for care by consumers who will become insured under the health law. Meanwhile, the Fiscal Times examines why some physicians are choosing not to accept any health insurance.

14 Jun 2013

PRISM Pharma announces closing of $15 million Series C financing

PRISM Pharma Co., Ltd., a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions, today announced the close of an approximately $15 million (approximately ¥1.4 billion) Series C financing.

13 Jun 2013

First Edition: June 13, 2013

Today's headlines include reports about how employers are preparing for some parts of the health law to kick in.

13 Jun 2013

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

New data from Boehringer Ingelheim’s interferon-free SOUND-C3 study were presented during the APASL Liver Week in Singapore. The Phase IIb study investigated the efficacy and safety of faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin in treatment-naïve patients with genotype-1b (GT-1b) hepatitis C virus (HCV),1 one of the most common types of HCV globally.2

13 Jun 2013

Cerus enrolls patient in two European clinical trials for INTERCEPT System for RBCs

Cerus Corporation announced today that it has initiated patient enrollment in two European Phase III clinical trials for the INTERCEPT System for red blood cells.

11 Jun 2013

Study shows iron-uptake receptor plays a role in HCV infection

Hepatitis C virus (HCV) infects more than 170 million people worldwide. Approximately 80 percent of infections lead to chronic illness including fibrosis, cirrhosis, cancer and also hepatic iron overload.

11 Jun 2013

3 out of 20 GI endoscopes used for screening harbor unacceptable levels of "bio dirt"

Three out of 20 flexible gastrointestinal (GI) endoscopes used for screening were found to harbor unacceptable levels of "bio dirt" - cells and matter from a patient's body that could pose potential infection risk -- according to a study of endoscopes used at five hospitals across the U.S.

10 Jun 2013

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

BioLineRx, a biopharmaceutical development company, announced today that it has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., the leading Chinese pharmaceutical company in the liver disease therapeutic area, for the development and commercialization of BL-8030, an orally available treatment for the Hepatitis C virus.

10 Jun 2013

Faldaprevir+ achieves viral cure in 88% of treatment-naïve genotype-1 hepatitis C patients in Asia

New findings presented today during the APASL Liver Week in Singapore, highlighted the efficacy and safety of faldaprevir+ plus pegylated interferon and ribavirin (PegIFN/RBV) in treatment-naïve patients with genotype-1 hepatitis C virus (HCV) in Asia.1 This post-hoc sub-analysis of the Phase III STARTVerso™1 and 2 trials showed that both doses of faldaprevir were associated with high viral cure rates and a shorter treatment duration in this particular patient group.1

10 Jun 2013

Liver regeneration using cell therapy may be possible, study suggests

Liver transplantation is the mainstay of treatment for patients with end-stage liver disease, the 12th leading cause of death in the United States, but new research from the Icahn School of Medicine at Mount Sinai, published in the online journal Cell Stem Cell today, suggests that it may one day become possible to regenerate a liver using cell therapy in patients with liver disease.

10 Jun 2013

Video promotes awareness about safe injection practices

A video depicting an animated man's harrowing experience with the healthcare system, including an avoidable unsafe injection, is the grand prize winner of the third annual Film Festival at the 40th Annual Conference of the Association for Professionals in Infection Control and Epidemiology (APIC).

7 Jun 2013

Hepatitis B News and Research

Latest Hepatitis B News and Research

Soligenix announces personalized medicine collaboration with SciClone

State highlights: Docs prescribe narcotics too often, CDC chief says; Fla. hospices get close scrutiny; Calif. Medi-Cal provider rate bump delayed

First Edition: July 3, 2013

UH and Case Western Reserve University to develop diagnostic tests to determine HIV drug resistance

New WHO guidelines recommend earlier treatment for people living with HIV

FDA to restrain shipments of pomegranate seeds from Turkey after hepatitis A outbreak

Health panel urges baby boomers be tested for hepatitis C

First Edition: June 25, 2013

Abbott RealTime HCV Genotype II assay receives FDA approval

Accenture: Boom ahead for retail health clinics

PRISM Pharma announces closing of $15 million Series C financing

First Edition: June 13, 2013

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

Cerus enrolls patient in two European clinical trials for INTERCEPT System for RBCs

Study shows iron-uptake receptor plays a role in HCV infection

3 out of 20 GI endoscopes used for screening harbor unacceptable levels of "bio dirt"

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

Faldaprevir+ achieves viral cure in 88% of treatment-naïve genotype-1 hepatitis C patients in Asia

Liver regeneration using cell therapy may be possible, study suggests

Video promotes awareness about safe injection practices

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Hepatitis B News and Research

Latest Hepatitis B News and Research

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Newsletters you may be interested in